Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
alanine/cancro da mama
O link é salvo na área de transferência
14 resultados
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology
2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
PRIMARY OBJECTIVES:
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.
SECONDARY OBJECTIVES:
I. To assess
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Inclusion criteria:
1. Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques
2. Histologically or cytologically confirmed tumor
3. Age of 18 years or more
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
5. Patients have failed,
Ribociclib and Bicalutamide in AR+ TNBC
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OUTLINE: This is a multi-center study.
INVESTIGATIONAL TREATMENT:
- bicalutamide - 150mg po daily D1 - D28 (Cycle = 28 days)
- ribociclib po daily D1 - D21 of 28 day cycle
PHASE I SAFETY RUN-IN COHORT:
The maximum tolerated dose (MTD) of bicalutamide in combination with ribociclib will be determined
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The FG-3019 treatment will be administered over a 28-day cycle:
- Dose: 35 mg/kg
- Route: IV over one hour following completion of gemcitabine infusion
- Schedule:
- Days 1, 8, and 15
- Please note that Day 8 infusion will on be completed during the first treatment cycle
On Drug Evaluation
The
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
1. Introduction to investigational treatment(s) and other study treatment(s)
1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OUTLINE: This is a multi-center trial.
INVESTIGATIONAL TREATMENT:
- Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
- Tamoxifen 20 mg will be administered orally once daily for every day of the
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OUTLINE: This is a multi-center trial.
SEQUENCING:
DNA from archived tumor samples collected at the time of surgery (residual disease post neoadjuvant chemotherapy) will be extracted and sequenced. The resulting sequencing data will be interrogated for known genomic drivers of sensitivity or
Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of mortality and morbidity in the intensive care unit (ICU). The causes of ALI/ARDS differ from patient to patient, including sepsis, aspiration, systemic inflammation, trauma, blood transfusion, etc. With
Physician Liver Function Test (LFT) Monitoring for Tykerb Pts
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OUTLINE: This is a multi-center study.
Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort 2). Patients in the safety run will be included in the efficacy analysis on intent to treat basis:
Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Head and neck squamous cell carcinoma (HNSCC) (excluding nasopharyngeal cancer) accounts for 4% to 5% of the cancer incidence in Taiwan.1 Localized disease is curable by surgery and irradiation. Two-thirds of patients present with advanced stages of the disease (stage III and IV), and are treated
Lonafarnib in Metastatic Breast Cancer
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OUTLINE: This is a multi-center study
Patients will be treated with lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
1 Cycle = 21 days of lonafarnib (plus the time required to recover from toxicity if
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
